Sven Reischauer1, Rima Arnaout2, Radhan Ramadass2, Didier Y R Stainier1. 1. From the Department of Biochemistry and Biophysics (S.R., D.Y.R.S.) and Division of Cardiology, Department of Medicine, Cardiovascular Research Institute (R.A.), University of California, San Francisco; and Department of Developmental Genetics, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany (S.R., R.R., D.Y.R.S.). sven.reischauer@mpi-bn.mpg.de didier.stainier@mpi-bn.mpg.de. 2. From the Department of Biochemistry and Biophysics (S.R., D.Y.R.S.) and Division of Cardiology, Department of Medicine, Cardiovascular Research Institute (R.A.), University of California, San Francisco; and Department of Developmental Genetics, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany (S.R., R.R., D.Y.R.S.).
Abstract
RATIONALE: Dilated cardiomyopathy is a leading cause of congestive heart failure and a debilitating complication of antineoplastic therapies. Despite disparate causes for dilated cardiomyopathy, maladaptive cardiac remodeling and decreased systolic function are common clinical consequences, begging an investigation of in vivo contractile dynamics in development and disease, one that has been impossible to date. OBJECTIVE: To image myocardial contractile filament dynamics in vivo and to assess potential causes of dilated cardiomyopathy in antineoplastic therapies targeting the epidermal growth factor receptor Erbb2. METHODS AND RESULTS: We generated a transgenic zebrafish line expressing an actin-binding green fluorescent protein in cardiomyocytes, allowing an in vivo imaging of myofilaments. Analysis of this line revealed architectural differences in myofibrils of the distinct cardiomyocyte subtypes. We used this model to investigate the effects of Erbb2 signaling on myofibrillar organization because drugs targeting ERBB2 (HER2/NEU) signaling, a mainstay of breast cancer chemotherapy, cause dilated cardiomyopathy in many patients. High-resolution in vivo imaging revealed that Erbb2 signaling regulates a switch between a dense apical network of filamentous myofibrils and the assembly of basally localized myofibrils in ventricular cardiomyocytes. CONCLUSIONS: Using this novel line, we compiled a reference for myofibrillar microarchitecture among myocardial subtypes in vivo and at different developmental stages, establishing this model as a tool to analyze in vivo cardiomyocyte contractility and remodeling for a broad range of cardiovascular questions. Furthermore, we applied this model to study Erbb2 signaling in cardiomyopathy. We show a direct link between Erbb2 activity and remodeling of myofibrils, revealing an unexpected mechanism with potentially important implications for prevention and treatment of cardiomyopathy.
RATIONALE: Dilated cardiomyopathy is a leading cause of congestive heart failure and a debilitating complication of antineoplastic therapies. Despite disparate causes for dilated cardiomyopathy, maladaptive cardiac remodeling and decreased systolic function are common clinical consequences, begging an investigation of in vivo contractile dynamics in development and disease, one that has been impossible to date. OBJECTIVE: To image myocardial contractile filament dynamics in vivo and to assess potential causes of dilated cardiomyopathy in antineoplastic therapies targeting the epidermal growth factor receptorErbb2. METHODS AND RESULTS: We generated a transgenic zebrafish line expressing an actin-binding green fluorescent protein in cardiomyocytes, allowing an in vivo imaging of myofilaments. Analysis of this line revealed architectural differences in myofibrils of the distinct cardiomyocyte subtypes. We used this model to investigate the effects of Erbb2 signaling on myofibrillar organization because drugs targeting ERBB2 (HER2/NEU) signaling, a mainstay of breast cancer chemotherapy, cause dilated cardiomyopathy in many patients. High-resolution in vivo imaging revealed that Erbb2 signaling regulates a switch between a dense apical network of filamentous myofibrils and the assembly of basally localized myofibrils in ventricular cardiomyocytes. CONCLUSIONS: Using this novel line, we compiled a reference for myofibrillar microarchitecture among myocardial subtypes in vivo and at different developmental stages, establishing this model as a tool to analyze in vivo cardiomyocyte contractility and remodeling for a broad range of cardiovascular questions. Furthermore, we applied this model to study Erbb2 signaling in cardiomyopathy. We show a direct link between Erbb2 activity and remodeling of myofibrils, revealing an unexpected mechanism with potentially important implications for prevention and treatment of cardiomyopathy.
Authors: D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich Journal: Science Date: 1989-05-12 Impact factor: 47.728
Authors: Ryuji Fukazawa; Thomas A Miller; Yukio Kuramochi; Stefan Frantz; Young Dae Kim; Mark A Marchionni; Ralph A Kelly; Douglas B Sawyer Journal: J Mol Cell Cardiol Date: 2003-12 Impact factor: 5.000
Authors: Eran R Andrechek; William R Hardy; Adele A Girgis-Gabardo; Robert L S Perry; Richard Butler; Frank L Graham; Ronald C Kahn; Michael A Rudnicki; William J Muller Journal: Mol Cell Biol Date: 2002-07 Impact factor: 4.272
Authors: Anoop V Cherian; Ryuichi Fukuda; Sruthy Maria Augustine; Hans-Martin Maischein; Didier Y R Stainier Journal: Proc Natl Acad Sci U S A Date: 2016-06-23 Impact factor: 11.205
Authors: Michael A Flinn; Cécile Otten; Zachary J Brandt; Jonathan R Bostrom; Aria Kenarsary; Tina C Wan; John A Auchampach; Salim Abdelilah-Seyfried; Caitlin C O'Meara; Brian A Link Journal: Development Date: 2020-08-25 Impact factor: 6.868